美国 · SEC FORM 4
Contineum Therapeutics, Inc.
CTNM · Nasdaq · CIK 0001855175 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
23 同一窗口内观察到的 Form 4 交易行
13 sales · 10 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
—
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot.—
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 3,067,588
- 上期报告
- 2,443,708
- 日均成交量
- 847,470
- 回补天数
- 3.6
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
本地 Form 4 历史中没有合资格的代码 P 股票买入。
Form 4 申报证据
51 transaction lines in the latest 365-day window; 58 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-08 | Stengone Carmine N. | 卖出 (S) | Class A Common Stock | 2,500 | USD 16.46 | USD 41,150 | SEC 申报 ↗ |
| 2026-09-08 | Stengone Carmine N. | 期权行权／转换 (M) | Class A Common Stock | 2,500 | USD 1.01 | USD 2,525 | SEC 申报 ↗ |
| 2026-08-03 | Stengone Carmine N. | 卖出 (S) | Class A Common Stock | 2,500 | USD 16.01 | USD 40,025 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-08 | Stengone Carmine N. | 卖出 (S) | Class A Common Stock | 2,500 | USD 16.46 | USD 41,150 | SEC 申报 ↗ |
| 2026-09-08 | Stengone Carmine N. | 期权行权／转换 (M) | Class A Common Stock | 2,500 | USD 1.01 | USD 2,525 | SEC 申报 ↗ |
| 2026-08-03 | Stengone Carmine N. | 卖出 (S) | Class A Common Stock | 2,500 | USD 16.01 | USD 40,025 | SEC 申报 ↗ |
| 2026-08-03 | Stengone Carmine N. | 期权行权／转换 (M) | Class A Common Stock | 2,500 | USD 1.01 | USD 2,525 | SEC 申报 ↗ |
| 2026-07-09 | Lorrain Daniel S. | 卖出 (S) | Class A Common Stock | 25 | USD 16.00 | USD 400 | SEC 申报 ↗ |
| 2026-07-09 | Lorrain Daniel S. | 期权行权／转换 (M) | Class A Common Stock | 25 | USD 1.01 | USD 25 | SEC 申报 ↗ |
| 2026-07-08 | Lorrain Daniel S. | 卖出 (S) | Class A Common Stock | 1,015 | USD 16.00 | USD 16,240 | SEC 申报 ↗ |
| 2026-07-08 | Lorrain Daniel S. | 期权行权／转换 (M) | Class A Common Stock | 1,015 | USD 1.01 | USD 1,025 | SEC 申报 ↗ |
| 2026-07-08 | Stengone Carmine N. | 卖出 (S) | Class A Common Stock | 2,500 | USD 16.00 | USD 40,000 | SEC 申报 ↗ |
| 2026-07-08 | Stengone Carmine N. | 期权行权／转换 (M) | Class A Common Stock | 2,500 | USD 1.01 | USD 2,525 | SEC 申报 ↗ |
| 2026-07-01 | Lorrain Daniel S. | 卖出 (S) | Class A Common Stock | 8,353 | USD 15.84 | USD 132,317 | SEC 申报 ↗ |
| 2026-07-01 | Lorrain Daniel S. | 期权行权／转换 (M) | Class A Common Stock | 4,183 | USD 1.01 | USD 4,225 | SEC 申报 ↗ |
| 2026-06-30 | Lorrain Daniel S. | 卖出 (S) | Class A Common Stock | 28,826 | USD 16.04 | USD 462,369 | SEC 申报 ↗ |
| 2026-06-30 | Lorrain Daniel S. | 期权行权／转换 (M) | Class A Common Stock | 28,826 | USD 1.01 | USD 29,114 | SEC 申报 ↗ |
| 2026-06-30 | Watkins Tim | 卖出 (S) | Class A Common Stock | 10,833 | USD 16.02 | USD 173,545 | SEC 申报 ↗ |
| 2026-06-30 | Watkins Tim | 期权行权／转换 (M) | Class A Common Stock | 10,833 | USD 4.50 | USD 48,748 | SEC 申报 ↗ |
| 2026-06-30 | Stengone Carmine N. | 卖出 (S) | Class A Common Stock | 10,000 | USD 16.01 | USD 160,100 | SEC 申报 ↗ |
| 2026-06-30 | Stengone Carmine N. | 期权行权／转换 (M) | Class A Common Stock | 10,000 | USD 1.07 | USD 10,725 | SEC 申报 ↗ |
| 2026-06-01 | Lorrain Daniel S. | 卖出 (S) | Class A Common Stock | 4,170 | USD 13.16 | USD 54,877 | SEC 申报 ↗ |
| 2026-05-01 | Lorrain Daniel S. | 卖出 (S) | Class A Common Stock | 4,170 | USD 13.12 | USD 54,694 | SEC 申报 ↗ |
| 2026-04-06 | Lorrain Daniel S. | 卖出 (S) | Class A Common Stock | 4,170 | USD 13.43 | USD 56,003 | SEC 申报 ↗ |
| 2026-03-02 | Watkins Tim | 卖出 (S) | Class A Common Stock | 3,611 | USD 15.02 | USD 54,237 | SEC 申报 ↗ |
| 2026-03-02 | Watkins Tim | 期权行权／转换 (M) | Class A Common Stock | 3,611 | USD 4.50 | USD 16,250 | SEC 申报 ↗ |
| 2026-03-02 | Lorrain Daniel S. | 卖出 (S) | Class A Common Stock | 4,170 | USD 15.01 | USD 62,592 | SEC 申报 ↗ |
| 2026-02-25 | Stengone Carmine N. | 卖出 (S) | Class A Common Stock | 2,700 | USD 16.02 | USD 43,254 | SEC 申报 ↗ |
| 2026-02-25 | Stengone Carmine N. | 期权行权／转换 (M) | Class A Common Stock | 2,700 | USD 1.26 | USD 3,402 | SEC 申报 ↗ |
| 2026-02-25 | Lorrain Daniel S. | 卖出 (S) | Class A Common Stock | 3,824 | USD 16.01 | USD 61,222 | SEC 申报 ↗ |
| 2026-02-25 | Lorrain Daniel S. | 期权行权／转换 (M) | Class A Common Stock | 3,824 | USD 1.01 | USD 3,862 | SEC 申报 ↗ |
| 2026-02-24 | Stengone Carmine N. | 卖出 (S) | Class A Common Stock | 4,400 | USD 16.02 | USD 70,488 | SEC 申报 ↗ |
| 2026-02-24 | Stengone Carmine N. | 期权行权／转换 (M) | Class A Common Stock | 4,400 | USD 1.26 | USD 5,544 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | CTNM |
| CIK | 0001855175 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 58 transaction lines from 2024-04-09 to 2026-09-08 0 P purchase lines · 34 S sale lines · 24 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.